<DOC>
	<DOCNO>NCT02859246</DOCNO>
	<brief_summary>It pilot study aim determine oral Mucinex® effective reducing amount corneal filament improve symptomology subject filamentary keratitis .</brief_summary>
	<brief_title>Mucinex® Treatment Filamentary Keratitis</brief_title>
	<detailed_description>The study aim determine oral administration Mucinex® effective reducing amount corneal filament improve symptomology subject filamentary keratitis . Subjects instruct take 600 mg tablet extend release Mucinex® twice day ( total dose 1.2 g/day ) 4 week .</detailed_description>
	<mesh_term>Keratitis</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Chlorpheniramine , phenylpropanolamine drug combination</mesh_term>
	<criteria>Patients filamentary keratitis 18 year older Active ocular surface infection type Recent ocular surgery ( &lt; 30 day ) history nephrolithiasis Mucinex® associate rare case development kidney stone Schirmer 's test &lt; 3mm History hypersensitivity Mucinex® Concurrent eye disease require immediate initiation new treatment ( e.g . topical steroid ) restriction water intake exacerbate risk nephrolithiasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>